Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early-Phase Oncology Drug Development.

Clin Pharmacol Ther · 2026 · PMC13339352 · PMID 41981759

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

c‐Myc showed a dose‐dependent increase in percentage of positive cells following LPS administration, whereas E‐cadherin showed a nonsignificant trend toward increase at both LPS doses compared with baseline ( Figure 6 b ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.